Xiaopeng Tian

机构：Sun Yat-sen University, Sun Yat-sen University Cancer Center · ORCID：0009-0009-4955-7807

发表论文 54 篇 · 总被引 355 次 · h-index 10

代表论文

• Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma (2023 · Nature Communications · 被引 41)
• First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial (2024 · The Lancet Haematology · 被引 33)
• Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint (2022 · Computational and Structural Biotechnology Journal · 被引 19)
• Toripalimab plus anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm phase 2 trial (TORAL) (2024 · Cell Reports Medicine · 被引 13)
• Identification of immune subtypes of Ph-neg B-ALL with ferroptosis related genes and the potential implementation of Sorafenib (2021 · BMC Cancer · 被引 13)
• Mercury release behaviors of Guizhou bituminous coal during co-pyrolysis: Influence of chlorella (2022 · Journal of Environmental Sciences · 被引 10)